Pacira BioSciences (PCRX)
(Delayed Data from NSDQ)
$27.21 USD
-0.11 (-0.40%)
Updated May 3, 2024 04:00 PM ET
After-Market: $27.22 +0.01 (0.04%) 7:58 PM ET
4-Sell of 5 4
A Value B Growth C Momentum A VGM
Brokerage Reports
Pacira BioSciences, Inc. [PCRX]
Reports for Purchase
Showing records 61 - 80 ( 717 total )
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
November Preliminary Sales; Additional EXPAREL Growth Potential in 2023
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Q3: Uncertainty Building in Elective Surgery Market; Pipeline Progress
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
3Q22: Surprising Manufacturing Hiccups Still; Apparently Resolved; Growth Prospects Intact; PT Tweaked Down to $76
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
3Q Soft Sales Pre-announce Not Surprising Given Macro Headwind; Still See Sequential Earnings Improvement; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Positive CHMP Opinion for EXPAREL in Children 6yo+, EU Approval Likely in Nov.
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Positive Results from Second Ph3 of EXPAREL/LENB; sNDA On-Track for Q1:23
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
August Preliminary Sales Show +14.2% Month-over-Month and +12.8% YoY Growth
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L